FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
ABSTRACT Background FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014). Method FXYD3 expressio...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70500 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543429522194432 |
|---|---|
| author | Nathalie B. Rasko Christopher B. Nahm John Turchini Rachel Teh Helge Rasmussen Sooin Byeon Sumit Sahni Jaswinder S. Samra Anthony J. Gill Anubhav Mittal |
| author_facet | Nathalie B. Rasko Christopher B. Nahm John Turchini Rachel Teh Helge Rasmussen Sooin Byeon Sumit Sahni Jaswinder S. Samra Anthony J. Gill Anubhav Mittal |
| author_sort | Nathalie B. Rasko |
| collection | DOAJ |
| description | ABSTRACT Background FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014). Method FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results 145 of 180 PDAC tumour specimens were FXYD3‐immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log‐rank p = 0.9718). FXYD3 expression correlated positively with late‐stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion Immunohistochemical FXYD3 expression does not predict survival in chemo‐naive PDAC patients, but is associated with late‐stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation. |
| format | Article |
| id | doaj-art-e048ce321f2f445b8a1a11247f47c1ca |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-e048ce321f2f445b8a1a11247f47c1ca2025-01-13T13:22:39ZengWileyCancer Medicine2045-76342025-01-01141n/an/a10.1002/cam4.70500FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict SurvivalNathalie B. Rasko0Christopher B. Nahm1John Turchini2Rachel Teh3Helge Rasmussen4Sooin Byeon5Sumit Sahni6Jaswinder S. Samra7Anthony J. Gill8Anubhav Mittal9Faculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaFaculty of Medicine and Health, Sydney Medical School University of Sydney Sydney New South Wales AustraliaABSTRACT Background FXYD3 is a Na/K‐ATPase modulator which is upregulated in pancreatic ductal adenocarcinoma (PDAC), but its prognostic role is unknown. This study evaluated FXYD3 expression in chemo‐naive patients with surgically‐resected PDAC at a single centre (1993–2014). Method FXYD3 expression was assessed in tumour specimens using immunohistochemistry. Results 145 of 180 PDAC tumour specimens were FXYD3‐immunopositive (80.5%). There was no difference in median overall survival between the FXYD3 negative (27.60 months) and positive groups (25.00 months) (log‐rank p = 0.9718). FXYD3 expression correlated positively with late‐stage disease (OR 3.041, 95% CI 1.190–7.455, p = 0.0175). There was no significant association with T stage, positive lymph nodes, perineural invasion, lymphovascular invasion or histological grade. Conclusion Immunohistochemical FXYD3 expression does not predict survival in chemo‐naive PDAC patients, but is associated with late‐stage disease. The high rate of FXYD3 overexpression warrants therapeutic evaluation.https://doi.org/10.1002/cam4.70500FXYD3MAT‐8pancreatic cancerpancreatic ductal adenocarcinomaprognosissurvival |
| spellingShingle | Nathalie B. Rasko Christopher B. Nahm John Turchini Rachel Teh Helge Rasmussen Sooin Byeon Sumit Sahni Jaswinder S. Samra Anthony J. Gill Anubhav Mittal FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival Cancer Medicine FXYD3 MAT‐8 pancreatic cancer pancreatic ductal adenocarcinoma prognosis survival |
| title | FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival |
| title_full | FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival |
| title_fullStr | FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival |
| title_full_unstemmed | FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival |
| title_short | FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival |
| title_sort | fxyd3 is frequently expressed in pancreatic ductal adenocarcinoma but does not predict survival |
| topic | FXYD3 MAT‐8 pancreatic cancer pancreatic ductal adenocarcinoma prognosis survival |
| url | https://doi.org/10.1002/cam4.70500 |
| work_keys_str_mv | AT nathaliebrasko fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT christopherbnahm fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT johnturchini fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT rachelteh fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT helgerasmussen fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT sooinbyeon fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT sumitsahni fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT jaswinderssamra fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT anthonyjgill fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival AT anubhavmittal fxyd3isfrequentlyexpressedinpancreaticductaladenocarcinomabutdoesnotpredictsurvival |